100mg-1000ct (100mg 1000ct)
Desvenlafaxine Tablet, Extended Release
Product Images NDC 70436-012
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 70436-012). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Slate Run Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
100mg-30ct (100mg 30ct)
Desvenlafaxine is a drug that comes in extended-release tablets containing 152 mg of desvenlafaxine succinate equivalent to 100 mg of desvenlafaxine. The usual dosage is not provided, so the package insert should be consulted. These tablets should be stored between 20° to 25°C (68° to 77°F) with excursions allowed to 15° to 30°C (59° to 86°F). They are manufactured in Hubei, China, and distributed by Slate Run Pharmaceuticals in Columbus, Ohio. A medication guide must be given to each patient.*
100mg-90ct (100mg 90ct)
Each tablet contains 152mg of desvenlafaxine succinate, which is equivalent to 100mg of desvenlafaxine. The usual dosage should be consulted in the package insert. The tablets should be stored at room temperature. They are manufactured in Yichang City, Hubei Province, China and distributed by State Run Pharmaceuticals, LLC in Columbus, Ohio.*
25mg 30ct
This is a description of a medication containing 38mg desvenlafaxine in an extended-release tablet form. Each tablet is equivalent to 25mg NDC 70436-036-04 Reony desvenlafaxine. It is advised to store the tablets at a temperature of 20°C to 25°C with extended excursions permitted to 16°C to 30°C. The medication guide should be provided to patients and the medication is distributed by Slate Run Pharmaceuticals, LLC in Columbus, Ohio.*
50mg-30ct (50mg 30ct)
Desvenlafaxine Extended-Release Tablets contain 76mg desvenlafaxine succinate equivalent to 50mg desvenlafaxine. Dosage instructions can be found in the package insert. Store the tablets at 20° to 25°C, with permitted excursions to 15° to 30°C. Manufactured in China, the tablets are distributed by Slate Run Pharmaceuticals in Columbus, Ohio. Always dispense the accompanying Medication Guide to each patient.*
50mg-90ct (50mg 90ct)
Desvenlafaxine is an extended-release tablet used as an antidepressant medicine. Each tablet contains 76 mg desvenlafaxine succinate, which is equivalent to 50 mg desvenlafaxine. The recommended dosage guidelines are provided in the package insert. It should be stored at 20° to 25°C and may be transferred within allowed excursions of 15° to 30°C. The drug comes in a package of 90 tablets manufactured in China by Yichang Humanwell Oral Solid Dosage Plant and distributed by Slate Run Pharmaceuticals, LLC in Columbus, Ohio. The medication guide needs to be dispensed to patients along with the medicine.*
Des-structure (Des Structure)
Figure-1 (Figure 1)
This text presents data on the geometric mean ratio (90% CI) for the maximum concentration and area under the curve for different degrees of renal and hepatic impairment, gender, and age ranges, compared to a reference. The data suggests that there is a change in pharmacokinetics for individuals with renal or hepatic impairment, females, and those in the 65-75 and >75 age ranges. ESRD is also included as a note.*
Figure-2 (Figure 2)
This is a chart that shows the change in Cmax (the maximum concentration) of Ketoconazole due to the inhibition of CYP3A4 by a PK change. The chart shows the geometric mean ratio (with a 90% confidence interval) for the change relative to the reference.*
Figure-3 (Figure 3)
This text appears to be a chart displaying various PK Geometric mean ratios (with 90% CI) for the drug Desvenlafaxine in interaction with other substances, such as CYP2D6, CYP3A4, tamoxifen, and aripiprazole, in different dosages. The ratios indicate changes in Desvenlafaxine's efficacy or concentration, compared to a reference substance. Specifically, the chart shows changes in Cmax and AUC for Desipramine, Midazolam, tamoxifen active metabolites, and aripiprazole active metabolites, across different doses.*
Figure-4 (Figure 4)
This is a graph that shows the estimated proportion of patients who experienced a relapse (in percentage) over time (in days from randomization), according to the treatment they received. The treatments compared were Desvenlafaxine Extended-Release Tablets 50 mg and Placebo. The graph shows that the proportion of patients experiencing relapse is lower in the Desvenlafaxine group compared to the Placebo group over time.*
Figure-5 (Figure 5)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
